For owners of durable medical equipment (DME) and home medical equipment (HME) companies, 2026 is shaping up to be an important transition year. Here are the developments that deserve the most attention:
1. Medicare Competitive Bidding Is Returning
The biggest industry story is the restart of the Medicare DMEPOS Competitive Bidding Program.
CMS has begun supplier education and preparation for a new bidding round during 2026, with contracts expected to be awarded in 2027 and become effective no later than January 1, 2028.
For DME suppliers, this means:
- Reviewing which product categories will be bid.
- Evaluating whether to participate in competitive bidding.
- Strengthening financial statements and compliance documentation.
- Preparing for increased competition from larger regional and national suppliers.
2. New Product Categories Are Being Added
CMS has finalized plans to include additional product categories in future competitive bidding, including:
- Urological supplies
- Ostomy supplies
- Certain remote item delivery (mail-order) products
These additions could significantly affect reimbursement and market dynamics for suppliers specializing in these products.
3. Greater Focus on Accreditation and Compliance
CMS is tightening supplier standards by updating:
- Accreditation requirements
- Provider enrollment standards
- Competitive bidding qualification requirements
Well-managed companies with strong compliance programs should be at an advantage, while marginal operators may struggle with the increased administrative burden.
4. Diabetes Technology Continues to Grow
Continuous glucose monitors (CGMs) and insulin pumps remain among the fastest-growing DME-related product categories.
CMS has adopted new payment classifications for these products, reflecting their growing importance in diabetes management.
Suppliers with expertise in diabetes care continue to have attractive growth opportunities.
5. Consolidation Is Accelerating
The DME industry continues to consolidate as larger regional and national providers acquire independent companies.
Active acquirers are seeking businesses with:
- Strong recurring revenue
- Respiratory therapy programs
- Sleep therapy (CPAP)
- Complex rehab
- Diabetes supplies
- Stable Medicare and commercial payer relationships
Many buyers view today’s regulatory changes as creating opportunities for scale and operational efficiency.
6. Technology Is Becoming a Competitive Advantage
Leading DME providers are investing heavily in:
- Electronic physician ordering
- Remote patient monitoring
- Automated resupply programs
- AI-assisted documentation
- Revenue cycle automation
- Digital patient engagement
Technology investments can improve compliance, reduce labor costs, and enhance patient retention.
7. Labor Remains Challenging
Many DME companies continue to face shortages of:
- Respiratory therapists
- Customer service staff
- Billing specialists
- Delivery technicians
Companies that automate routine workflows are generally better positioned to manage these staffing challenges.
8. Valuations Remain Strong for Quality Businesses
Demand for well-run DME companies remains healthy, particularly for businesses with:
- Net Income above $1 million
- Diversified referral sources
- Strong recurring revenue
- Clean compliance history
- Modern billing systems
- Consistent cash flow
Private equity firms and strategic buyers continue to pursue acquisitions, especially in specialty DME segments such as respiratory care, diabetes management, complex rehab, wound care, and home-based chronic disease management.
What DME Owners Should Be Thinking About
If you own a DME company, the priorities over the next 18–24 months should include:
- Preparing for the next competitive bidding cycle.
- Maintaining impeccable compliance and accreditation.
- Diversifying referral sources and payer mix.
- Investing in automation and operational efficiency.
- Evaluating acquisition opportunities—or preparing your business for a potential sale while buyer demand remains strong.
Overall, 2026 is less about immediate reimbursement changes and more about positioning. Companies that enter the next competitive bidding cycle with strong financials, efficient operations, and solid compliance programs are likely to be in the strongest position to grow—or command premium valuations if they choose to sell.
Want to chat about your specific DME? Call me, Jim King, at 888-565-6468